CAS: 1446113-23-0

Belvarafenib (HM95573) is a potent pan-RAF inhibitor with antitumor activity and inhibits B-RAF, B-RAFv600E, and C-RAF.Cost-effective and quality-assured.

Belvarafenib

Belvarafenib is a targeted therapeutic compound categorized as a novel RAF kinase inhibitor. It is sourced through chemical synthesis, designed specifically to target and inhibit aberrant kinase activity in cancer cells. The mode of action involves the selective inhibition of the RAF protein kinases, particularly BRAF, which play a pivotal role in the MAPK/ERK signaling pathway. By interrupting this signal transduction cascade, Belvarafenib effectively halts the proliferation of cancerous cells harboring specific BRAF mutations. The primary applications of Belvarafenib are in oncology, where it is utilized to treat cancers with identified RAF mutations, such as melanoma. Its specificity reduces off-target effects, making it a precise therapeutic option. Current research is exploring its combination with other targeted therapies to enhance efficacy and overcome resistance mechanisms. As an expert in the field, it is crucial to consider the molecular basis and genetic profiles of tumors when implementing Belvarafenib, optimizing its use within the landscape of personalized medicine.

4-Amino-N-(1-((3-Chloro-2-Fluorophenyl)Amino)-6-Methylisoquinolin-5-Yl)Thieno[3,2-D]Pyrimidine-7-Carboxamide